Hopital NOVO

Hopital NOVO is conducting studies to improve treatment of severe lung infections, including a trial that compares cotrimoxazole with standard care for ventilator‑associated pneumonia and another evaluating a novel inhaled therapy for Mycobacterium xenopi pulmonary disease.

• Ventilator‑associated pneumonia de‑escalation study
• Mycobacterium xenopi pulmonary infection trial
• Early Pseudomonas aeruginosa eradication in bronchiectasis

The department’s 39 investigators are advancing antimicrobial research to reduce ICU mortality and resistance.

At this site, researchers focus on aggressive gastrointestinal cancers, testing refined neo‑adjuvant chemotherapy protocols for locally advanced colon cancer and evaluating modified regimens for small bowel adenocarcinoma to enhance long‑term survival.

• Colon cancer neo‑adjuvant therapy trial
• Small bowel adenocarcinoma phase II study
• Digestive system physiological monitoring

These trials aim to personalize treatment for older patients and improve postoperative outcomes.

The oncology program investigates innovative immunotherapy for high‑risk breast cancer, including a peptide‑based vaccine that targets HER2/neu to prevent disease recurrence after standard trastuzumab therapy.

• HER2‑positive breast cancer peptide vaccine trial
• High‑risk residual disease study
• Oncology trial collaboration network

By integrating novel agents with existing standards, the team seeks to increase disease‑free survival.

A comparative study evaluates the effectiveness of rituximab versus ocrelizumab in relapsing‑remitting multiple sclerosis, with the goal of confirming non‑inferior disease control over two years.

• Relapsing‑remitting MS non‑inferiority trial
• B‑cell targeted therapy assessment
• Neurology research network coordination

The trial supports evidence‑based choices for long‑term management of MS patients.

Investigations address progressive interstitial lung disease and bronchiectasis, testing a single course of rituximab to preserve lung function and comparing antibiotic regimens to eradicate early Pseudomonas infection.

• Progressive ILD with inflammatory component study
• Bronchiectasis PA infection management trial
• Respiratory intensive care research initiatives

These efforts aim to slow disease progression and improve quality of life for patients with chronic lung conditions.

Complementary research explores physiological processes of the digestive tract and oral cavity, supporting the broader oncology and gastrointestinal programs through detailed biomarker and functional assessments.

• Digestive system physiological monitoring
• Oral health considerations in cancer care
• Cross‑disciplinary investigative studies

This integrated approach enhances understanding of treatment impacts beyond primary disease sites.